ofloxacin has been researched along with Cholera Infantum in 17 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this comparative trial, outpatients with acute sinusitis were randomly assigned to receive levofloxacin (500 mg orally once daily) or amoxicillin-clavulanate (500/125 mg orally 3 times daily) for 10 to 14 days." | 9.09 | Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. ( Adelglass, J; Campbell, T; DeAbate, CA; Fowler, CL; LoCocco, J; McElvaine, P, 1999) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 7.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "In this comparative trial, outpatients with acute sinusitis were randomly assigned to receive levofloxacin (500 mg orally once daily) or amoxicillin-clavulanate (500/125 mg orally 3 times daily) for 10 to 14 days." | 5.09 | Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. ( Adelglass, J; Campbell, T; DeAbate, CA; Fowler, CL; LoCocco, J; McElvaine, P, 1999) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 3.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "Ofloxacin treatment was used for the treatment of lower respiratory tract infections in 35 patients." | 2.67 | Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. ( Regamey, C; Steinbach-Lebbin, C, 1990) |
| " In all, 130 adverse reactions have been recorded in 116 patients (5." | 2.66 | Safety profile of ofloxacin: the Italian data base. ( Fostini, R; Granata, F; Koverech, A; Picari, M; Recchia, G; Toniolo, D, 1986) |
| "Levofloxacin was associated with a mild effect on the normal microflora, reaching a maximum at four days of therapy, with complete recovery being achieved by seven days post-therapy." | 2.41 | A comparison of side effects of levofloxacin to other agents concerning the ecological and microbiological effects on normal human flora. ( Acar, JF, 2001) |
| "We studied the pharmacokinetic and pharmacodynamic parameters of levofloxacin and rifampicin in bone and joint infections." | 1.38 | Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ( Bensalem, M; Bland, S; Bru, JP; Gaillat, J; Garraffo, R; Guillaume, M; Janssen, C, 2012) |
| "aeruginosa from respiratory tract infections at 13-21%, which was the same trend as in past years." | 1.35 | [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007]. ( Aihara, M; Akiyama, T; Akizawa, K; Aoki, Y; Asano, Y; Baba, H; fujimoto, Y; Fujita, J; Fujita, S; Fujiwara, H; Genma, H; Gonda, H; Haruki, K; Hashikita, G; Hayashi, M; Heijyou, H; Hida, Y; Hiramatsu, K; Horiuchi, H; Ichiyama, S; Idomuki, M; Ieiri, T; Ikeda, N; Inuzuka, K; Iriyama, J; Ishii, Y; Ito, T; Iwata, M; Kaku, M; Kamioka, M; Kanda, M; Kang, D; Kanno, H; Katayama, Y; Kato, J; Kawahara, K; Kawamura, C; Kawano, S; Kawashima, C; Kinoshita, S; Kobayashi, Y; Kohno, S; Koike, K; Kon, S; Kondou, S; Kono, H; Kumasaka, K; Kusaba, K; Kusakabe, T; Kusano, N; Kuwabara, M; Maekawa, M; Maesaki, S; Masaki, H; Mashiba, K; Matsuda, J; Matsuda, K; Matsuo, S; Miki, M; Misawa, S; Miyajima, E; Miyanohara, H; Moro, K; Murakami, M; Murase, M; Murata, M; Nagai, A; Nakagawa, T; Nakamura, K; Nakashima, Y; Nakasone, I; Nakatani, K; Nakaya, H; Negayama, K; Ohno, A; Oka, M; Okabe, H; Okada, M; Okamoto, H; Okamoto, Y; Okayama, A; Okazaki, T; Okubo, S; Ono, J; Ota, H; Ozaki, Y; Saikawa, T; Saito, T; Sano, R; Sekine, I; Shigeta, M; Shimizu, C; Shiotani, J; Soma, M; Sugita, A; Sugiura, T; Sumitomo, M; Suwabe, A; Takubo, T; Taniguchi, N; Tashiro, H; Tateda, K; Tazawa, Y; Tominaga, M; Toyoshima, S; Uchida, T; Yamaguchi, I; Yamaguchi, K; Yamahata, K; Yamamoto, G; Yamamoto, Y; Yamane, N; Yamashita, M; Yamazaki, K; Yanagihara, K; Yasujima, M; Yoneyama, A; Yoshida, H; Yoshimura, H; Yuzuki, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, K | 1 |
| Ohno, A | 1 |
| Ishii, Y | 1 |
| Tateda, K | 1 |
| Iwata, M | 1 |
| Kanda, M | 1 |
| Akizawa, K | 1 |
| Shimizu, C | 1 |
| Kon, S | 1 |
| Nakamura, K | 1 |
| Matsuda, K | 1 |
| Tominaga, M | 1 |
| Nakagawa, T | 1 |
| Sugita, A | 1 |
| Ito, T | 1 |
| Kato, J | 1 |
| Suwabe, A | 1 |
| Yamahata, K | 1 |
| Kawamura, C | 1 |
| Tashiro, H | 1 |
| Horiuchi, H | 2 |
| Katayama, Y | 1 |
| Kondou, S | 1 |
| Misawa, S | 1 |
| Murata, M | 1 |
| Kobayashi, Y | 1 |
| Okamoto, H | 1 |
| Yamazaki, K | 1 |
| Okada, M | 1 |
| Haruki, K | 1 |
| Kanno, H | 1 |
| Aihara, M | 1 |
| Maesaki, S | 1 |
| Hashikita, G | 1 |
| Miyajima, E | 1 |
| Sumitomo, M | 1 |
| Saito, T | 1 |
| Yamane, N | 2 |
| Kawashima, C | 1 |
| Akiyama, T | 1 |
| Ieiri, T | 1 |
| Yamamoto, Y | 1 |
| Okamoto, Y | 1 |
| Okabe, H | 1 |
| Moro, K | 1 |
| Shigeta, M | 1 |
| Yoshida, H | 1 |
| Yamashita, M | 1 |
| Hida, Y | 1 |
| Takubo, T | 1 |
| Kusakabe, T | 1 |
| Masaki, H | 1 |
| Heijyou, H | 1 |
| Nakaya, H | 1 |
| Kawahara, K | 1 |
| Sano, R | 1 |
| Matsuo, S | 1 |
| Kono, H | 1 |
| Yuzuki, Y | 1 |
| Ikeda, N | 1 |
| Idomuki, M | 1 |
| Soma, M | 1 |
| Yamamoto, G | 1 |
| Kinoshita, S | 1 |
| Kawano, S | 1 |
| Oka, M | 1 |
| Kusano, N | 1 |
| Kang, D | 1 |
| Ono, J | 1 |
| Yasujima, M | 1 |
| Miki, M | 1 |
| Hayashi, M | 1 |
| Okubo, S | 1 |
| Toyoshima, S | 1 |
| Kaku, M | 1 |
| Sekine, I | 1 |
| Shiotani, J | 1 |
| Tazawa, Y | 1 |
| Yoneyama, A | 1 |
| Kumasaka, K | 1 |
| Koike, K | 1 |
| Taniguchi, N | 1 |
| Ozaki, Y | 1 |
| Uchida, T | 1 |
| Murakami, M | 1 |
| Inuzuka, K | 1 |
| Gonda, H | 1 |
| Yamaguchi, I | 1 |
| fujimoto, Y | 1 |
| Iriyama, J | 1 |
| Asano, Y | 1 |
| Genma, H | 1 |
| Maekawa, M | 1 |
| Yoshimura, H | 1 |
| Nakatani, K | 1 |
| Baba, H | 1 |
| Ichiyama, S | 1 |
| Fujita, S | 1 |
| Kuwabara, M | 1 |
| Okazaki, T | 1 |
| Fujiwara, H | 1 |
| Ota, H | 1 |
| Nagai, A | 1 |
| Fujita, J | 1 |
| Negayama, K | 1 |
| Sugiura, T | 1 |
| Kamioka, M | 1 |
| Murase, M | 1 |
| Nakasone, I | 1 |
| Okayama, A | 1 |
| Aoki, Y | 1 |
| Kusaba, K | 1 |
| Nakashima, Y | 1 |
| Miyanohara, H | 1 |
| Hiramatsu, K | 1 |
| Saikawa, T | 1 |
| Yanagihara, K | 1 |
| Matsuda, J | 1 |
| Kohno, S | 1 |
| Mashiba, K | 1 |
| Pontone, S | 1 |
| Standoli, M | 1 |
| Angelini, R | 1 |
| Pontone, P | 1 |
| Guillaume, M | 1 |
| Garraffo, R | 1 |
| Bensalem, M | 1 |
| Janssen, C | 1 |
| Bland, S | 1 |
| Gaillat, J | 1 |
| Bru, JP | 1 |
| Zubkov, MN | 1 |
| Iakovlev, VP | 1 |
| Svetukhin, AM | 1 |
| Blatun, LA | 1 |
| Ukhin, SA | 1 |
| Adelglass, J | 1 |
| DeAbate, CA | 1 |
| McElvaine, P | 1 |
| Fowler, CL | 1 |
| LoCocco, J | 1 |
| Campbell, T | 1 |
| Marrie, TJ | 1 |
| Lau, CY | 1 |
| Wheeler, SL | 1 |
| Wong, CJ | 1 |
| Feagan, BG | 1 |
| Acar, JF | 1 |
| Stahlmann, R | 1 |
| Lou, HX | 1 |
| Shullo, MA | 1 |
| McKaveney, TP | 1 |
| Regamey, C | 1 |
| Steinbach-Lebbin, C | 1 |
| Neu, HC | 1 |
| Blomer, R | 1 |
| Bruch, K | 1 |
| Krauss, H | 1 |
| Wacheck, W | 1 |
| Koverech, A | 1 |
| Picari, M | 1 |
| Granata, F | 1 |
| Fostini, R | 1 |
| Toniolo, D | 1 |
| Recchia, G | 1 |
| Jüngst, G | 1 |
| Mohr, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens[NCT05454345] | Phase 3 | 620 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
4 reviews available for ofloxacin and Cholera Infantum
| Article | Year |
|---|---|
Levofloxacin revisited.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Gastrointestinal Diseases; Humans; Levofloxaci | 2011 |
[Efficacy and safety of levofloxacin in low respiratory tract infection].
Topics: Anti-Bacterial Agents; Central Nervous System Diseases; Clinical Trials as Topic; Dermatitis, Atopic | 2004 |
[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Ciprofloxacin; Gastro | 2004 |
A comparison of side effects of levofloxacin to other agents concerning the ecological and microbiological effects on normal human flora.
Topics: Anti-Infective Agents; Digestive System; Drug Resistance, Microbial; Ecology; Enterococcus; Gastroin | 2001 |
6 trials available for ofloxacin and Cholera Infantum
| Article | Year |
|---|---|
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Am | 1999 |
Predictors of symptom resolution in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gastro | 2000 |
Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study.
Topics: Adolescent; Adult; Aged; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; M | 1990 |
Safety profile of ofloxacin: the Italian data base.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Drug Eruptions; Female; Ga | 1986 |
Side effects of ofloxacin in clinical trials and in postmarketing surveillance.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Hypersensitivity; Evaluation Studies as Topic; | 1987 |
7 other studies available for ofloxacin and Cholera Infantum
| Article | Year |
|---|---|
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007].
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; G | 2009 |
Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Arthritis, Infectious; Body Mass Index; Discit | 2012 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; | 1997 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.
Topics: Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; | 2002 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
Safety of ofloxacin--adverse drug reactions reported during phase-II studies in Europe and in Japan.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Drug Eruptions; Drug Evaluation; Europe; Female; Gas | 1986 |